Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Fe65-PTB2 Dimerization Mimics Fe65-APP Interaction
Lukas P Feilen1, Kevin Haubrich1,2, Paul Strecker3
1Heidelberg University Biochemistry Center (BZH), University of HeidelbergHeidelberg, Germany.
Abstract:
Physiological function and pathology of the Alzheimer's disease causing amyloid precursor protein (APP) are correlated with its cytosolic adaptor Fe65 encompassing a WW and two phosphotyrosine-binding domains (PTBs). The C-terminal Fe65-PTB2 binds a large portion of the APP intracellular domain (AICD) including the GYENPTY internalization sequence fingerprint. AICD binding to Fe65-PTB2 opens an intra-molecular interaction causing a structural change and altering Fe65 activity. Here we show that in the absence of the AICD, Fe65-PTB2 forms a homodimer in solution and determine its crystal structure at 2.6 Å resolution. Dimerization involves the unwinding of a C-terminal α-helix that mimics binding of the AICD internalization sequence, thus shielding the hydrophobic binding pocket. Specific dimer formation is validated by nuclear magnetic resonance (NMR) techniques and cell-based analyses reveal that Fe65-PTB2 together with the WW domain are necessary and sufficient for dimerization. Together, our data demonstrate that Fe65 dimerizes via its APP interaction site, suggesting that besides intra- also intermolecular interactions between Fe65 molecules contribute to homeostatic regulation of APP mediated signaling.
Insights
Fe65 protein dimerizes through its APP-binding site, revealing a new mechanism for regulating Alzheimer
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) involves amyloid precursor protein (APP) and its adaptor Fe65.
- Fe65 has WW and phosphotyrosine-binding (PTB) domains, with PTB2 binding APP intracellular domain (AICD).
- AICD binding alters Fe65 structure and activity.
Purpose of the Study:
- Investigate Fe65-PTB2 dimerization in the absence of AICD.
- Determine the structural basis of Fe65-PTB2 homodimerization.
- Explore the role of Fe65 dimerization in APP signaling.
Main Methods:
- Crystal structure determination of Fe65-PTB2 at 2.6 Å resolution.
- Nuclear magnetic resonance (NMR) spectroscopy.
- Cell-based assays.
Main Results:
- Fe65-PTB2 forms a homodimer in solution without AICD.
- Dimerization involves unwinding of a C-terminal α-helix, mimicking AICD binding.
- Fe65-PTB2 and WW domain are essential and sufficient for dimerization.
- NMR and cell-based studies validate Fe65 dimerization.
Conclusions:
- Fe65 dimerizes via its APP-binding site, suggesting intermolecular interactions are crucial.
- Fe65 dimerization offers a novel regulatory mechanism for APP signaling in AD.
- Understanding Fe65 dimerization may lead to new therapeutic strategies for Alzheimer's disease.
More Related Videos
Related Concept Videos
Noncovalent Attractions in Biomolecules
Noncovalent Attractions in Biomolecules
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Valence Bond Theory

